血管质量倡议评估Bard LifeStent治疗腘动脉闭塞性疾病
在美国29个VQI中心开展单臂前瞻性试验,2016年11月至2019年5月纳入74例腘动脉(P1-P3段)闭塞性疾病患者,评估Bard LifeStent自膨式支架。1年免于主要不良事件82%、免于靶病变血运重建86%,结论认为该支架在P2、P3段腘动脉挑战性解剖中表现良好。
要点
- 1年免于主要不良事件82%、免于靶病变血运重建86%、免于靶血管血运重建84%。
- 1年一期通畅率80%、二期通畅率89%,持续临床成功率98%、持续血流动力学成功率100%。
- 所有死亡和主要截肢均发生在慢性肢体威胁性缺血患者中。
核心结论
- 在这项多中心、基于注册的单臂前瞻性研究中,Bard LifeStent自膨式支架在P2和P3段腘动脉的挑战性解剖中表现出良好的性能。
- 外周血管介入器械标签扩展的上市后研究可在血管外科学会VQI注册系统中成功开展。
研究设计与样本
- 单臂前瞻性试验,在美国29个VQI中心开展,2016年11月至2019年5月纳入74例患者。
- 主要安全性结局为1年免于主要不良事件(包括器械/操作相关死亡和主要截肢)。
- 主要有效性结局为1年免于靶血管血运重建和免于靶病变血运重建。
- 次要结局包括病变成功、操作成功、一期/一期辅助/二期通畅率、持续临床成功(Rutherford分级改善)和持续血流动力学成功(踝肱指数增加>0.10)。
- 结局采用Kaplan-Meier分析评估,接受靶病变血运重建患者的动脉造影由核心实验室评估支架断裂。
主要发现
- 平均年龄71岁,男性63.5%,糖尿病55%,间歇性跛行28%、慢性肢体威胁性缺血72%。
- 支架置入于股浅动脉-腘动脉者38%、仅腘动脉者62%;多数支架置于P1+P2段(39%)或P1+P2+P3段(37%)。
- 免于主要不良事件1年82%、2年74%;免于死亡1年100%、2年97%;免于主要截肢1年100%、2年90%,所有死亡和主要截肢均发生在慢性肢体威胁性缺血患者中。
- 12个月免于靶病变血运重建86%、免于靶血管血运重建84%;出院时病变治疗成功99%、操作成功82%。
- 12个月和24个月一期通畅率均为80%和72%,一期辅助通畅率均为80%和72%,二期通畅率分别为89%和82%;持续临床成功分别为98%和95%,持续血流动力学成功分别为100%和79%。
关键数值与推荐
- 主要安全性终点免于主要不良事件1年82%、2年74%。
- 主要有效性终点12个月免于靶病变血运重建86%、免于靶血管血运重建84%。
- 12个月和24个月一期通畅率80%和72%,一期辅助通畅率80%和72%,二期通畅率89%和82%。
- 12个月和24个月持续临床成功率98%和95%,持续血流动力学成功率100%和79%。
- 出院时病变治疗成功99%、操作成功82%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Bard LifeStent self-expanding stent is approved for the treatment of occlusive disease involving the superficial femoral artery and proximal popliteal artery. We conducted a post-market trial of treatment of the popliteal artery above and below the knee (P1, P2, and P3 segments) within the Society for Vascular Surgery Vascular Quality Initiative (VQI) Peripheral Vascular Intervention registry. METHODS: A single-arm, prospective trial was conducted at 29 VQI sites in the United States, enrolling 74 patients from November 2016 to May 2019. The primary safety outcome was freedom from major adverse events including device-/procedure-related mortality and major amputation at 1 year. The primary efficacy outcomes were freedom from target vessel revascularization and freedom from target lesion revascularization at 1 year. Secondary outcomes included lesion success; procedural success; primary, primary-assisted, and secondary patency; and sustained clinical (improvement in Rutherford class) and hemodynamic success (increase in ankle brachial index >0.10). Outcomes were assessed by Kaplan-Meier analysis. Arteriogram of patients undergoing target lesion revascularization were assessed for stent fracture by a core laboratory. RESULTS: The mean age was 71 years, with 63.5% male and 55% with diabetes. The indication was claudication 28% and chronic limb-threatening ischemia in 72%. The superficial femoral artery-popliteal artery was stented in 38% and the popliteal artery alone in 62%. The majority of stents were placed in the P1 + P2 (39%) or P1 + P2 + P3 (37%) segments of the popliteal artery. The composite primary endpoint of freedom from major adverse events was 82% and 74% at 1 and 2 years, respectively. Freedom from mortality was 100% and 97%, and freedom from major amputation was 100% and 90% at 1 and 12 months, with all deaths and major amputations occurring in patients with chronic limb-threatening ischemia. freedom from target lesion revascularization was 86%, and freedom from target vessel revascularization was 84% at 12 months. At discharge, lesion treatment success was 99%, and procedural success was 82%. Primary patency was 80% and 72%, primary-assisted patency was 80% and 72%, and secondary patency was 89% and 82% at 12 and 24 months. Sustained clinical success was 98% and 95%, and sustained hemodynamic success was 100% and 79% at 12 and 24 months. CONCLUSIONS: In this multi-center, registry-based, single-arm prospective study the Bard LifeStent self-expanding stent demonstrated favorable performance in the challenging anatomy of the P2 and P3 popliteal segment. Post-market studies for label expansion of peripheral vascular intervention devices can be successfully conducted within the Society for Vascular Surgery VQI registry.
引用
- Bertges DJ, Eldrup-Jorgensen J, Eskandari MK, et al. The Vascular Quality Initiative assessment of the Bard Lifestent for the treatment of popliteal artery occlusive disease. J Vasc Surg. 2023. PMID: 37648091. doi:10.1016/j.jvs.2023.08.122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。